Novo Nordisk launches oral Wegovy in Spain at €236, seeks state funding

Novo Nordisk has launched its oral formulation of Wegovy in Spain, priced at €236 and available only by prescription in pharmacies. The company is negotiating with Spanish health authorities for public funding, which would expand access but strain budgets. This marks a significant step in the obesity drug market's European expansion.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works